Factor VIII and IX assays for post-infusion monitoring in hemophilia patients: Guidelines from the French BIMHO group (GFHT).
Factor IX
Factor VIII
chronometric and chromogenic assays
haemophilia A
haemophilia B
Journal
European journal of haematology
ISSN: 1600-0609
Titre abrégé: Eur J Haematol
Pays: England
ID NLM: 8703985
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
received:
12
01
2020
revised:
01
04
2020
accepted:
02
04
2020
pubmed:
12
4
2020
medline:
2
6
2021
entrez:
12
4
2020
Statut:
ppublish
Résumé
Replacement therapy with plasma-derived or recombinant FVIII and FIX (pdFVIII/pdFIX or rFVIII/rFIX) concentrates is the standard of treatment in patients with haemophilia A and B, respectively. Measurement of factor VIII (FVIII:C) or factor IX (FIX:C) levels can be done by one-stage clotting assay (OSA) or chromogenic substrate assay (CSA). The French study group on the Biology of Hemorrhagic Diseases (a collaborative group of the GFHT and MHEMO network) presents a literature review and proposals for the monitoring of FVIII:C and FIX:C levels in treated haemophilia A and B patients, respectively. The use of CSA is recommended for the monitoring of patients treated with pdFVIII or rFVIII including extended half-life (EHL) rFVIII. Except for rFVIII-Fc, great caution is required when measuring FVIII:C levels by OSA in patients substituted by EHL-rFVIII. The OSA is recommended for the monitoring of patients treated with pdFIX or rFIX. Large discordances in the FIX:C levels measured for extended half-life rFIX (EHL-rFIX), depending on the method and reagents used, must lead to great attention when OSA is used for measuring FIX:C levels in patients substituted by EHL-rFIX. Data of most of recent studies, obtained with spiked plasmas, deserve to be confirmed in plasma samples of treated patients.
Substances chimiques
Recombinant Proteins
0
Factor VIII
9001-27-8
Factor IX
9001-28-9
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
103-115Investigateurs
Martine Alhenc Gelas
(MA)
Christine Biron
(C)
Florence Blanc-Jouvan
(F)
Evelyne Bourgerette
(E)
Benedicte Bulabois
(B)
Emilie Comio
(E)
Magali Donnard
(M)
Jerôme Duchemin
(J)
Anne-Camille Faure
(AC)
François Grand
(F)
Lelia Grunebaum
(L)
Maryse Guicheteau
(M)
Felipe Guerrero
(F)
Nathalie Hezard
(N)
Marie-Françoise Hurtaud
(MF)
Fabienne Nedelec Gac
(F)
Emmanuel De Maistre
(E)
Raphael Marlu
(R)
Guillaume Mourey
(G)
Perrine Munier
(P)
Fabienne Pineau-Vincent
(F)
Didier Raffenot
(D)
Yohan Repesse
(Y)
Anne Ryman
(A)
Laurent Sattler
(L)
Pauline Sauguet
(P)
Anne-Francoise Serre-Sapin
(AF)
Alain Stepanian
(A)
Jean Szymezak
(J)
Marie Toussaint-Hacquart
(M)
Marie Tuffigo
(M)
Annelise Voyer
(A)
Informations de copyright
© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Caron C, Dautzenberg M-D, Delahousse B, et al. A blinded in vitro study with Refacto mock plasma samples: similar FVIII results between the chromogenic assay and a one-stage assay when using a higher cephalin dilution. Haemophilia. 2002;8:639-643.
Dawson NJ, Kemball-Cook G, Barrowcliffe TW. Assay discrepancies with highly purified factor VIII concentrates. Haemostasis. 1989;19:131-137.
Van den Bossche D, Peerlinck K, Jacquemin M. New challenges and best practices for the laboratory monitoring of factor VIII and factor IX replacement. Int J Lab Hematol. 2018;40:21-29.
Hubbard AR, Dodt J, Lee T, et al. Recommendations on the potency labelling of factor VIII and factor IX concentrates. J Thromb Haemost. 2013;11:988-989.
Barrowcliffe TW, Raut S, Sands D, Hubbard AR. Coagulation and chromogenic assays of factor VIII activity: general aspects, standardization, and recommendations. Semin Thromb Hemost. 2002;28:247-256.
Kitchen S, Kershaw G, Tiefenbacher S. Recombinant to modified factor VIII and factor IX - chromogenic and one-stage assays issues. Haemophilia. 2016;22:72-77.
Adcock DM, Strandberg K, Shima M, Marlar RA. Advantages, disadvantages and optimization of one-stage and chromogenic factor activity assays in haemophilia A and B. Int J Lab Hematol. 2018;40:621-629.
Martinuzzo M, Barrera L, Rodriguez M, D’Adamo MA, López MS, Otaso JC. Do PT and APTT sensitivities to factors’ deficiencies calculated by the H47-A2 2008 CLSI guideline reflect the deficiencies found in plasmas from patients? Int J Lab Hematol. 2015;37:853-860.
Toulon P, Eloit Y, Smahi M, et al. In vitro sensitivity of different activated partial thromboplastin time reagents to mild clotting factor deficiencies. Int J Lab Hematol. 2016;38:389-396.
Aznar JA, Cabrera N, Matysiak M, et al. Pharmacokinetic study of a high-purity factor IX concentrate (Factor IX Grifols) with a 6-month follow up in previously treated patients with severe haemophilia B. Haemophilia. 2009;15:1243-1248.
Berntorp E, Björkman S, Carlsson M, Lethagen S, Nilsson IM. Biochemical and in vivo properties of high purity factor IX concentrates. Thromb Haemost. 1993;70:768-773.
Bowyer AE, Hillarp A, Ezban M, Persson P, Kitchen S. Measuring factor IX activity of nonacog beta pegol with commercially available one-stage clotting and chromogenic assay kits: a two-center study. J Thromb Haemost. 2016;14:1428-1435.
Wilmot HV, Hogwood J, Gray E. Recombinant factor IX: discrepancies between one-stage clotting and chromogenic assays. Haemophilia. 2014;20:891-897.
Mikaelsson M, Oswaldsson U. Assaying the circulating factor VIII activity in haemophilia A patients treated with recombinant factor VIII products. Semin Thromb Hemost. 2002;28:257-264.
Dodt J, Hubbard AR, Wicks SJ, et al. Potency determination of factor VIII and factor IX for new product labelling and postinfusion testing: challenges for caregivers and regulators. Haemophilia. 2015;21:543-549.
Turecek PL, Abbühl B, Tangada SD, et al. Nonacog gamma, a novel recombinant factor IX with low factor IXa content for treatment and prophylaxis of bleeding episodes. Expert Rev Clin Pharmacol. 2015;8:163-177.
Kitchen S, Gray E, Mertens K. Monitoring of modified factor VIII and IX products. Haemophilia. 2014;20:36-42.
Kitchen S, Katterle Y, Beckmann H, Maas EM. Chromogenic assay for BAY 81-8973 potency assignment has no impact on clinical outcome or monitoring in patient samples. J Thromb Haemost. 2016;14:1192-1199.
Turecek PL, Romeder-Finger S, Apostol C, et al. A world-wide survey and field study in clinical haemostasis laboratories to evaluate FVIII: C activity assay variability of ADYNOVATE and OBIZUR in comparison with ADVATE. Haemophilia. 2016;22:957-965.
St. Ledger K, Feussner A, Kalina U, et al. International comparative field study evaluating the assay performance of AFSTYLA in plasma samples at clinical hemostasis laboratories. J Thromb Haemost. 2018;16:555-564.
Sommer JM, Moore N, McGuffie-Valentine B, et al. Comparative field study evaluating the activity of recombinant factor VIII Fc fusion protein in plasma samples at clinical haemostasis laboratories. Haemophilia. 2014;20:294-300.
Pouplard C, Ternisien C, Desconclois C, Lasne D, Aillaud M-F, Caron C. Discrepancies between one stage assay and chromogenic substrate assay in patients treated with recombinant or plasma-derived FVIII and usefulness of a specific standard in ReFacto AF®-treated patients. Haemophilia. 2016;22:e101-e103.
Viuff D, Barrowcliffe T, Saugstrup T, Ezban M, Lillicrap D. International comparative field study of N8 evaluating factor VIII assay performance. Haemophilia. 2011;17:695-702.
Lusher JM, Hillman-Wiseman C, Hurst D. In vivo recovery with products of very high purity - assay discrepancies. Haemophilia. 1998;4:641-645.
Kitchen S, Jennings I, Makris M, Kitchen DP, Woods TA, Walker ID. Factor VIII assay variability in postinfusion samples containing full length and B-domain deleted FVIII. Haemophilia. 2016;22:806-812.
Kitchen S, Beckmann H, Katterle Y, Bruns S, Tseneklidou-Stoeter D, Maas EM. BAY 81-8973, a full-length recombinant factor VIII: results from an international comparative laboratory field study. Haemophilia. 2016;22:e192-e199.
Pouplard C, Caron C, Aillaud MF, et al. The use of the new ReFacto AF Laboratory Standard allows reliable measurement of FVIII: C levels in ReFacto AF mock plasma samples by a one-stage clotting assay. Haemophilia. 2011;17:e958-e962.
Cauchie M, Toelen J, Peerlinck K, Jacquemin M. Practical and cost-effective measurement of B-domain deleted and full-length recombinant FVIII in the routine haemostasis laboratory. Haemophilia. 2013;19:e133-e138.
Pickering W, Hansen M, Kjalke M, Ezban M. Factor VIII chromogenic assays can be used for potency labeling and postadministration monitoring of N8-GP. J Thromb Haemost. 2016;14:1579-1587.
Klukowska A, Szczepański T, Vdovin V, Knaub S, Jansen M, Liesner R. Novel, human cell line-derived recombinant factor VIII (Human-cl rhFVIII, Nuwiq®) in children with severe haemophilia A: efficacy, safety and pharmacokinetics. Haemophilia. 2016;22:232-239.
Kershaw GW, Dissanayake K, Chen VM, Khoo T-L. Evaluation of chromogenic factor IX assays by automated protocols. Haemophilia. 2018;24:492-501.
Gritsch H, Romeder-Finger S, Scheiflinger F, Turecek PL. Potency assignment and measurement of recombinant FIX activity in human plasma impact of reagents on the 1-stage clotting assay. Haemophilia. 2014;Suppl 3:37.
Sommer J, Buyue Y, Bardan S, et al. Comparative field study: impact of laboratory assay variability on the assessment of recombinant factor IX Fc fusion protein (rFIXFc) activity. Thromb Haemost. 2014;112:932-940.
Mahlangu J, Powell JS, Ragni MV, et al. Phase 3 study of recombinant factor VIII Fc fusion protein in severe haemophilia A. Blood. 2014;123:317-325.
Powell JS, Josephson NC, Quon D, et al. Safety and prolonged activity of recombinant factor VIII Fc fusion protein in haemophilia A patients. Blood. 2012;119:3031-3037.
Young G, Mahlangu J, Kulkarni R, et al. Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe haemophilia A. J Thromb Haemost. 2015;13:967-977.
Pouplard C, Sattler L, Ryman A, et al. Multicentre pharmacokinetic evaluation of rFVIII-Fc (efmoroctocog alpha) in a real life and comparison with non-extended half-life FVIII concentrates. Haemophilia. 2020;26(2):282-289.
Bulla O, Poncet A, Alberio L, et al. Impact of a product-specific reference standard for the measurement of a PEGylated rFVIII activity: the Swiss Multicentre Field Study. Haemophilia. 2017;23:e335-e339.
Gu J-M, Ramsey P, Evans V, et al. Evaluation of the activated partial thromboplastin time assay for clinical monitoring of PEGylated recombinant factor VIII (BAY 94-9027) for haemophilia A. Haemophilia. 2014;20:593-600.
Church N, Leong L, Katterle Y, et al. Factor VIII activity of BAY 94-9027 is accurately measured with most commonly used assays: results from an international laboratory study. Haemophilia. 2018;24:823-832.
Hillarp A, Bowyer A, Ezban M, Persson P, Kitchen S. Measuring FVIII activity of glycopegylated recombinant factor VIII, N8-GP, with commercially available one-stage clotting and chromogenic assay kits: a two-centre study. Haemophilia. 2017;23:458-465.
Bowyer A, Key N, Dalton D, Kitchen S, Makris M. The coagulation laboratory monitoring of Afstyla single-chain FVIII concentrate. Haemophilia. 2017;23:e469-e470.
Persson A, Mahmoud Hourani Soutari N, Norberg E-M, Antovic J. One stage and chromogenic assays discrepancy in the estimation of factor IX (FIX) recovery. What is it that a single haemophilia center can and cannot do? Res Pract Thromb Haemost. 2018;2:120.
Dericquebourg A, Jourdy Y, Negrier C, Nougier C. Comparison of three assays for measuring factor IX. Haemophilia. 2018;24:51.
Willemze A, Sadeghi-Khomami A, Sörskog L, Wikén M, Lethagen S. Assessment of clotting activity of recombinant fix FC fusion protein in European haemophilia treatment centers. Haemophilia. 2018;24:55.
Bowyer A, Sampson B, Shepherd F, Jones R, Kitchen S, Makris M. The FIX C assessment of extended half-life recombinant factor IX products in clinical practice. Haemophilia. 2018;24:56.
St Ledger K, Fuessner A, Kalina U, et al. Performance of a recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in the one-stage assay. Haemophilia. 2016;22:59.
Buyue Y, Rabinovich D, Bardan S, et al. Product-specific calibration standards do not correct one-stage clotting assay discrepancies for modified recombinant FIX molecules with reagents that significantly over- or under-recover labeled potency. Annual Meeting of the Scientific Standardization Committee of of the International Society on Thrombosis and Haemostasis. ISTH SSC, May 25-28, Montpellier, France 2016; 14: 52.
Pouplard C, Galinat H, Ternisien C, et al. Multicentre evaluation of CK Prest® for assaying plasma levels of factor IX fused with albumin (Idelvion®). Haemophilia. 2019;25:e327-e330.
Florin L, Devreese KMJ. Comparison of two one-stage clotting assays and one chromogenic FIX assay for monitoring of Idelvion® Replacement therapy. Volume 2, Issue S1. Abstracts of the 64th Annual Meeting of the Scientific Standardization Committeeof the International Society on Thrombosis and Haemostasis, July 18-21, 2018.
Vangenechten M, Maes M, Maes M, Gadisseur A.Differences in activity of plasma spiked with IDELVION® generated with one-stage clotting assay using different commercial APTT reagents compared with chromogenic method. Volume 2, Issue S1. Abstracts of the 64th Annual Meeting of the Scientific Standardization Committee of the International Society on Thrombosis and Haemostasis, July 18-21, 2018 (Internet). 2018. Available from: https://onlinelibrary.wiley.com/doi/pdf/10.1002/rth2.12125.
Horn C, Négrier C, Kalina U, Seifert W, Friedman KD. Performance of a recombinant fusion protein linking coagulation factor IX with recombinant albumin in one-stage clotting assays. J Thromb Haemost. 2019;17:138-148.
Rosén P, Rosén S, Ezban M, Persson E. Overestimation of N-glycoPEGylated factor IX activity in a one-stage factor IX clotting assay owing to silica-mediated premature conversion to activated factor IX. J Thromb Haemost. 2016;14:1420-1427.
Persson E, La Cour CC. Underestimation of N-glycoPEGylated factor IX one-stage clotting activity owing to contact activator-impaired activation. Res Pract Thromb Haemost. 2017;1:259-263.
Young G, Ezban M, Clausen WHO, Negrier C, Oldenburg J, Shima M. Chromogenic analysis of FIX activity in haemophilia B patients treated with nonacog beta pegol. Haemophilia. 2017;23:e528-e530.
Tiefenbacher S, Bohra R, Amiral J, et al. Qualification of a select one-stage activated partial thromboplastin time-based clotting assay and two chromogenic assays for the post-administration monitoring of nonacog beta pegol. J Thromb Haemost. 2017;15:1901-1912.
Gray E, Kitchen S, Bowyer A, et al. Laboratory measurement of factor replacement therapies in the treatment of congenital haemophilia: a United Kingdom Haemophilia Centre Doctors’ Organisation guideline. Haemophilia. 2020;26:6-16.
Kitchen S, Tiefenbacher S, Gosselin R. Factor activity assays for monitoring extended half-life FVIII and factor IX replacement therapies. Semin Thromb Hemost. 2017;43:331-337.
Peyvandi F, Oldenburg J, Friedman KD. A critical appraisal of one-stage and chromogenic assays of factor VIII activity. J Thromb Haemost. 2016;14:248-261.
Hermans C, Altisent C, Batorova A, et al. Replacement therapy for invasive procedures in patients with haemophilia: literature review, European survey and recommendations. Haemophilia. 2009;15:639-658.
Kitchen S, Signer-Romero K, Key NS. Current laboratory practices in the diagnosis and management of haemophilia: a global assessment. Haemophilia. 2015;21:550-557.
Marlar RA, Strandberg K, Shima M, Adcock DM. Clinical utility and impact of the use of the chromogenic vs one-stage factor activity assays in haemophilia A and B. Eur J Haematol. 2020;104:3-14.